Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Operating Leases (2023 - 2025)

Axsome Therapeutics' Operating Leases history spans 3 years, with the latest figure at $23.2 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 283.43% year-over-year to $23.2 million; the TTM value through Dec 2025 reached $23.2 million, up 283.43%, while the annual FY2025 figure was $23.2 million, 283.43% up from the prior year.
  • Operating Leases for Q4 2025 was $23.2 million at Axsome Therapeutics, up from $23.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $23.9 million in Q1 2025 and bottomed at $6.0 million in Q4 2024.
  • The 3-year median for Operating Leases is $7.5 million (2023), against an average of $13.0 million.
  • The largest annual shift saw Operating Leases fell 16.27% in 2024 before it skyrocketed 283.43% in 2025.
  • A 3-year view of Operating Leases shows it stood at $7.0 million in 2023, then dropped by 14.06% to $6.0 million in 2024, then surged by 283.43% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Operating Leases are $23.2 million (Q4 2025), $23.0 million (Q3 2025), and $23.6 million (Q2 2025).